HER-Vaxx has completed Ph2, PD1-Vaxx has just started Ph2 this year and CF33 and Azer-Cel is schedule to complete Ph1/b end of this year so yes they are many years away from even getting their IP to Ph3 completion which is why investors in biotech start-up stock tend to invest in them for a T/O by BP as the IP advance in development.
Usually, only BP will have the fund and resource to complete Ph3 clinical trial but CF33 seem to be very different so it could follow a different path to commercialisation like Azer-Cel so both might not need 5 years but a few years from Ph2.
HER-Vaxx has completed Ph2, PD1-Vaxx has just started Ph2 this...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
0.002(2.82%) |
Mkt cap ! $541.6M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.6¢ | 7.1¢ | $732.7K | 9.942M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 1576364 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 299591 | 6 |
View Market Depth
| Last trade - 10.56am 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.3¢ |
Change
0.002 ( 2.24 %) |
||||
| Open | High | Low | Volume | ||
| 7.1¢ | 7.6¢ | 7.1¢ | 4757052 | ||
| Last updated 11.15am 17/05/2024 ? | |||||
| IMU (ASX) Chart |